Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764198 versus placebo in primary or TRPC6-related FSGS
NL-OMON61016Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing BI 764198 with Placebo (2 arms). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NL-OMON61016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61016.